Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Drug Profile

Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Alternative Names: BCMA GoCAR-NK - Bellicum Pharmaceuticals; BPX 401; BPX 602; BPX-802; BPZ-2003; CaspaCIDe-enabled CD19 CAR; CaspaCIDe® T Cell immunotherapies - Bellicum Pharmaceuticals; Chemical Induction of Dimerization enabled cellular immunotherapies - Bellicum Pharmaceuticals; CIDeCar#1; DeCIDe® based immunotherapies - Bellicum pharmaceuticals; DS GoCAR-T cells - Bellicum Pharmaceuticals; Dual-Switch CAR-T Cells; Dual-switch GoCAR-T cells - Bellicum Pharmaceuticals; GoCAR-T based immunotherapies - Bellicum Pharmaceuticals

Latest Information Update: 07 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Haematological malignancies; Solid tumours

Most Recent Events

  • 05 Dec 2020 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)
  • 31 Oct 2020 Suspended - Preclinical for Haematological malignancies in USA (IV)
  • 31 Oct 2020 Suspended - Preclinical for Solid tumours in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top